BRAF and neoplasm: Exposure of BRAF V600E driven melanoma cells to sublethal levels to the BRAF inhibitor vemurafenib or the DNA damaging agent cisplatin led to the development of a less differentiated, drug-tolerant state characterized by the enrichment of slow-cycling, long-term tumor-maintaining melanoma cells.